Biodesix, Inc.

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 52 percent increase over losses of $(0.50) per share from the same period last year. The company

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.

https://www.scribd.com/document/635988578/BDSX-Patent

Guidance represents anticipated 36-44% growth over 2022 total revenue from Lung Diagnostic testing, Biopharmaceutical Services and COVID-19 testing; Excluding 2022 COVID-19 testing

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.28) by 25 percent. This is a 28.57 percent increase over losses of $(0.49) per share from the same

Companies Reporting Before The Bell • Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.

The Federal Reserve on Wednesday raised its benchmark rate by 0.25%, marking the central bank's second consecutive policy downshift. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.